Background Thrombus is highly prevalent in patients with recent symptoms (<6 months) of claudication or limb ischemia and occluded culprit lower extremity vessels. Treatment of these thrombotic occlusions is challenging….
Background Target lesion revascularization (TLR) with primary percutaneous transluminal angioplasty (PTA) vs. cryoplasty (CRYO) in the treatment of de novo infrainguinal disease has not been well defined in randomized trials….
Background Patients undergoing administration of thrombolytic therapy for deep venous thrombosis (DVT) have been reported to have major bleeding rates of 5%–10%. These results stem from older data with dosing…
Background Patients (pts) undergoing pacemaker and/or cardioverter–defibrillator (PM/ICD) implantation/upgrade might have difficult access due to sub/total central vein occlusions, usually related to prior venous manipulation. This study aimed to describe…
Background There is currently a paucity of data regarding clinical outcomes after everolimus-eluting stent (EES) implantation [compared to paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES)] in unselected patients with the…
Background The Zilver PTX stent with polymer-free paclitaxel coating is the first drug-eluting stent approved (currently CE marked, investigational in the United States and Japan) for the superficial femoral artery…
Background Both high on-treatment platelet reactivity and periprocedural myocardial infarction (MI) are associated with adverse events following percutaneous coronary intervention (PCI). The optimal method of quantifying platelet reactivity remains controversial….
Background Patients with lesions located in small vessels are at increased risk of adverse outcomes after PCI. Improved safety and efficacy have been previously demonstrated with XIENCE V stents in…
Hydrogen sulfide (H 2 S) is a novel gaseous signaling molecule that up-regulates antioxidants, anti-apoptogens, and promotes cellular survival. In the heart, cystathionine gamma-lyase (CSE) is the primary enzyme for…
Background Severe aortic stenosis (AS) patients with left ventricular ejection fraction (LVEF) <20% are currently excluded from transcatheter aortic valve implant trials and are believed to be at higher risk…
